BOLT — Bolt Biotherapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1641281 ·
Last close
$5.65
Market Cap
$14.73M
52W High
$7.78
52W Low
$3.10
ADV30
512,850
Next earnings
—
Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company offers product candidates and platform technologies, including PRA-216, BDC-4182, a Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; the Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, and the INSPIRE platform. It serves patients, clinical investigators, and biopharmaceutical partners. The company is based in Redwood City, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 5,000 — -7,566,000 -7,720,000 40,344,000 12,860,000 27,704,000
Mar 2026 26,000 — -7,601,000 -7,244,000 48,027,000 11,609,000 28,205,000
Dec 2025 2,500,000 — -5,605,000 -6,631,000 56,748,000 11,703,000 30,243,000
Sep 2025 2,169,000 — -7,703,000 -7,144,000 65,053,000 17,753,000 32,952,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-31,451,000
Investing CF
$34,653,000
Financing CF
$30,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-16.44
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-475,743,000
Inventory
—
Receivables
$973,000
ST Investments
$4,738,000
EBIT TTM
$-28,475,000
Pretax Income TTM
$-28,739,000
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,700,000
EBITDA
$-27,556,000
Free Cash Flow
$-18,791,876
Enterprise Value
$18,044,790
Total Cash
$14,798,000
Total Debt
$20,889,000
Shares Out
2,607,490
Trailing EPS
$-16.51
Book Value
$4.36
ROE
-111.6%
ROA
-30.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 7,695,000 -34,633,000 -33,376,000 56,748,000 30,243,000 26,505,000 -39,850,000
Dec 2024 7,690,000 -68,236,000 -63,118,000 99,632,000 42,434,000 57,198,000 -61,289,000
Dec 2023 7,876,000 -76,196,000 -69,197,000 159,784,000 47,043,000 112,741,000 -69,525,000
Dec 2022 5,729,000 -90,321,000 -88,098,000 227,807,000 56,301,000 171,506,000 -76,504,000

TTM Snapshot

Revenues TTM
$4,700,000
NetIncome TTM
$-28,739,000
OpCashFlow TTM
—
Assets (Latest)
$40,344,000
Forward EPS
$-20.19

Peers — same industry

TickerNameMarket CapLastDaily %
MDNAF Medicenna Therapeutics Corp. $14.77M $0.16 —
KTTA Pasithea Therapeutics Corp. $14.51M $0.43 —
MCRB Seres Therapeutics, Inc. $14.37M $1.41 —
CTXR Citius Pharmaceuticals, Inc. $14.24M $0.52 —
NCEL NewcelX Ltd. $15.48M $2.68 —

News headlines (Yahoo Finance, 1h cache)

Bolt Biotherapeutics, Inc.: Q3 Earnings Snapshot
2026-11-12 21:56 · Yahoo
Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 21:05 · Yahoo
Bolt Biotherapeutics to Participate in Upcoming Conferences
2026-11-03 13:00 · Yahoo
Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications
2026-10-23 13:08 · Yahoo
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates
2026-08-11 21:45 · Yahoo
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-11 20:05 · Yahoo
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-12 20:05 · Yahoo
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates
2026-05-12 21:40 · Yahoo
Metastatic HER2-Positive Breast Cancer Market Expected to Surge at a CAGR of 8.3% During the Forecast Period (2026–2036) Due to Advancing Targeted Treatments | DelveInsight
2026-06-01 17:00 · Yahoo
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
2026-11-09 22:35 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-11-17 20:42:48 2026-11-16 Coastlands Capital LP 10% P - Purchase 5.84 53094 309922